Drug
Broncho-Vaxom clinical trials
Also written OM-85.
Keep track of what changes. Save the Broncho-Vaxom studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 10
Medical University of Lublin (3) · Lallemand Pharma AG (2) · University of Arizona (1) · University of North Carolina, Chapel Hill (1) · The University of Queensland (1) · Chinese Academy of Medical Sciences (1) · Vifor Pharma (1) · Kecioren Education and Training Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Broncho-Vaxom is read from its arms, and is right about nine times in ten.
Testing it · 14
- Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.RecruitingPhase 3Franciscus GasthuisNCT05063149Written as Broncho-Vaxom
- Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract IllnessCompletedPhase 2University of ArizonaNCT02148796Written as Broncho-Vaxom (BV)
- PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyCompletedPhase 2University of North Carolina, Chapel HillNCT04129931Written as Broncho-Vaxom
- Immunomodulation by OM-85 (Broncho-Vaxom) in Early ADTerminatedPhase 2OM Pharma SANCT05222516Written as Broncho-Vaxom
- Effect of Bacterial Lysate on Nasal Carriage of Staphylococcus AureusCompletedPhase 3Medical University of LublinNCT04637425Written as Ismigen
- The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT CellsCompletedPhase 3Medical University of LublinNCT04802616Written as Ismigen
- Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85CompletedPhase 3The University of QueenslandNCT04496245Written as Broncho-Vaxom®
- Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic SyndromeStatus unknownNot applicableFang DengNCT05044169Written as Broncho-Vaxom
- Efficacy Of Bacterial Lysate In Children With Allergic RhinitisCompletedPhase 3Medical University of LublinNCT04270552Written as Ismigen
- Prevention of OM-85 on Bronchiectasis ExacerbationCompletedPhase 4Chinese Academy of Medical SciencesNCT01968421Written as OM-85 BV
- Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic DermatitisCompletedPhase 3Vifor PharmaNCT03047954Written as Broncho-Vaxom
- Efficacy Of Bacterial Lysate In Asthmatic ChildrenCompletedPhase 3Lallemand Pharma AGNCT02541331Written as ISMIGEN
- Advanced Immunological Approach in COPD ExacerbationCompletedPhase 4Lallemand Pharma AGNCT02417649Written as Ismigen
- Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent WheezingCompletedPhase 4Kecioren Education and Training HospitalNCT00733226Written as OM-85 BV (Broncho-Vaxom)
Codes
What other systems call Broncho-Vaxom · ClinicalTrials.gg INT002913
- MeSH (NLM) C030259Broncho-VaxomOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C030259 | Broncho-Vaxom | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.